激素替代疗法对有骨质疏松症风险因素的诺丁汉绝经后女性的可接受性。
Hormone replacement therapy acceptability to Nottingham post-menopausal women with a risk factor for osteoporosis.
作者信息
Wallace W A, Price V H, Elliot C A, MacPherson M B, Scott B W
机构信息
Department of Orthopaedic & Accident Surgery, University Hospital, Queen's Medical Centre, Nottingham.
出版信息
J R Soc Med. 1990 Nov;83(11):699-701. doi: 10.1177/014107689008301109.
Abstract
In Nottingham we have assessed the acceptability of oral hormone replacement therapy (HRT) for an at risk group of post-menopausal women for osteoporosis. One hundred post-menopausal women between the ages of 50 and 70 years who had sustained a distal radial fracture were offered oral HRT. There was a 36% overall uptake of HRT with 9% of patients unable to take HRT because they had medical contraindications. The uptake in the 50-55 year age group was 54%. We conclude that in prospective studies of HRT for osteoporosis up to 50% of patients may not wish to take HRT and therefore study design should allow for this level of uptake.
摘要
在诺丁汉，我们评估了口服激素替代疗法（HRT）对有骨质疏松症风险的绝经后女性群体的可接受性。100名年龄在50至70岁之间、桡骨远端发生骨折的绝经后女性被提供了口服HRT。HRT的总体接受率为36%，9%的患者因有医学禁忌证而无法接受HRT。50 - 55岁年龄组的接受率为54%。我们得出结论，在关于HRT治疗骨质疏松症的前瞻性研究中，高达50%的患者可能不希望接受HRT，因此研究设计应考虑到这一接受水平。
相似文献
1
Hormone replacement therapy acceptability to Nottingham post-menopausal women with a risk factor for osteoporosis.激素替代疗法对有骨质疏松症风险因素的诺丁汉绝经后女性的可接受性。
J R Soc Med. 1990 Nov;83(11):699-701. doi: 10.1177/014107689008301109.
2
Women's knowledge of and attitudes towards hormone replacement therapy.女性对激素替代疗法的了解及态度。
Fam Pract. 2003 Apr;20(2):112-9. doi: 10.1093/fampra/20.2.112.
3
Postmenopausal osteoporosis and hormone replacement therapy.绝经后骨质疏松症与激素替代疗法
Minerva Med. 2004 Dec;95(6):507-20.
4
Attitudes to osteoporosis and hormone replacement therapy among elderly women.
Osteoporos Int. 1999;9(2):139-43. doi: 10.1007/s001980050127.
5
Women's decisions about hormone replacement therapy after education and bone densitometry.接受教育并进行骨密度测量后女性关于激素替代疗法的决定。
CMAJ. 1998 Nov 17;159(10):1253-7.
6
Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial.妇女健康倡议试验公布后绝经后妇女激素替代疗法的使用情况
J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):460-2. doi: 10.1093/gerona/60.4.460.
7
The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.激素替代疗法对绝经后早期女性骨折风险的保护作用受雌激素受体α基因型的调节。
J Bone Miner Res. 2000 Dec;15(12):2479-86. doi: 10.1359/jbmr.2000.15.12.2479.
8
Compliance considerations with hormone replacement therapy.激素替代疗法的依从性考量
Menopause. 1998 Summer;5(2):102-6.
9
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].[激素替代疗法及选择性雌激素受体调节剂（SERMs）在绝经后骨质疏松症防治中的应用]
Orthopade. 2001 Jul;30(7):462-72. doi: 10.1007/s001320170079.
10
Physician counseling on hormone replacement therapy and bone loss: do socioeconomic and racial characteristics of women influence counseling?医生关于激素替代疗法和骨质流失的咨询：女性的社会经济和种族特征会影响咨询吗？
J Womens Health (Larchmt). 2003 Jun;12(5):495-504. doi: 10.1089/154099903766651621.
引用本文的文献
1
Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis.雷洛昔芬预防和治疗骨质疏松症的依从性及持续率的观察性研究。
Curr Ther Res Clin Exp. 2004 Nov;65(6):470-80. doi: 10.1016/j.curtheres.2005.01.003.
2
Axial BMD, change in BMD and bone turnover do not predict breast cancer incidence in early postmenopausal women.轴向骨密度、骨密度变化和骨转换不能预测绝经后早期女性的乳腺癌发病率。
Osteoporos Int. 2005 Dec;16(12):1627-32. doi: 10.1007/s00198-005-1886-4. Epub 2005 Mar 22.
3
Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.
Pharmacoeconomics. 1998 Nov;14(5):559-73. doi: 10.2165/00019053-199814050-00007.
4
Population screening for osteoporosis to prevent fractures.为预防骨折而进行的骨质疏松症人群筛查。
Qual Health Care. 1992 Mar;1(1):77-80. doi: 10.1136/qshc.1.1.77.
5
Hormone replacement therapy in the aged. A state of the art review.
Drugs Aging. 1996 Mar;8(3):193-213. doi: 10.2165/00002512-199608030-00005.
6
Osteoporosis will never be a disease of the past.
Osteoporos Int. 1994;4 Suppl 1:3-4. doi: 10.1007/BF01623427.
7
Treatment of osteoporosis: current and future.骨质疏松症的治疗：现状与未来。
Ann Rheum Dis. 1991 Oct;50(10):663-5. doi: 10.1136/ard.50.10.663.
8
Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits.激素替代疗法与乳腺癌、子宫内膜癌及心血管疾病：风险与益处
Br J Gen Pract. 1992 Mar;42(356):120-5.
本文引用的文献
1
Fracture frequency and bone preservation in postmenopausal women treated with estrogen.接受雌激素治疗的绝经后女性的骨折发生率及骨质保存情况。
Obstet Gynecol. 1982 Oct;60(4):493-6.
2
The effect of estrogen dose on postmenopausal bone loss.雌激素剂量对绝经后骨质流失的影响。
N Engl J Med. 1983 Dec 8;309(23):1405-7. doi: 10.1056/NEJM198312083092301.
3
Noncontraceptive estrogen use and the risk of breast cancer.非避孕雌激素的使用与乳腺癌风险
JAMA. 1984 Jul 6;252(1):63-7.
4
Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy.绝经后妇女停用雌激素/孕激素替代疗法后的骨量
Lancet. 1981 Feb 28;1(8218):459-61. doi: 10.1016/s0140-6736(81)91848-1.
5
Menopausal oestrogens and breast cancer risk: an expanded case-control study.更年期雌激素与乳腺癌风险：一项扩大的病例对照研究。
Br J Cancer. 1986 Nov;54(5):825-32. doi: 10.1038/bjc.1986.246.
6
Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.髋部骨折与绝经后女性雌激素的使用。弗明汉姆研究。
N Engl J Med. 1987 Nov 5;317(19):1169-74. doi: 10.1056/NEJM198711053171901.
7
Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy.接受激素替代疗法的女性的死亡率和癌症发病率的长期监测。
Br J Obstet Gynaecol. 1987 Jul;94(7):620-35. doi: 10.1111/j.1471-0528.1987.tb03166.x.
8
Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis.雌激素替代疗法I：一项关于其与骨质疏松症关系的10年前瞻性研究。
Obstet Gynecol. 1979 Mar;53(3):277-81.
9
Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment.
Lancet. 1976 May 15;1(7968):1038-41. doi: 10.1016/s0140-6736(76)92217-0.
Zotero 插件